Lifeworks Advisors LLC Has $5.51 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Lifeworks Advisors LLC reduced its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 11,853 shares of the pharmaceutical company’s stock after selling 560 shares during the period. Vertex Pharmaceuticals accounts for about 1.1% of Lifeworks Advisors LLC’s portfolio, making the stock its 26th largest holding. Lifeworks Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $5,512,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Tokio Marine Asset Management Co. Ltd. increased its holdings in Vertex Pharmaceuticals by 8.0% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 7,681 shares of the pharmaceutical company’s stock worth $3,572,000 after buying an additional 566 shares during the last quarter. Metis Global Partners LLC increased its stake in shares of Vertex Pharmaceuticals by 8.1% during the 3rd quarter. Metis Global Partners LLC now owns 13,455 shares of the pharmaceutical company’s stock worth $6,258,000 after purchasing an additional 1,007 shares during the last quarter. Curi RMB Capital LLC lifted its stake in Vertex Pharmaceuticals by 4.7% in the 3rd quarter. Curi RMB Capital LLC now owns 1,580 shares of the pharmaceutical company’s stock valued at $735,000 after purchasing an additional 71 shares during the last quarter. Aubrey Capital Management Ltd bought a new position in Vertex Pharmaceuticals during the third quarter worth about $3,209,000. Finally, KBC Group NV increased its position in Vertex Pharmaceuticals by 11.1% during the third quarter. KBC Group NV now owns 96,727 shares of the pharmaceutical company’s stock worth $44,986,000 after buying an additional 9,685 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Vertex Pharmaceuticals

In other news, Chairman Jeffrey M. Leiden sold 3,784 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the completion of the sale, the chairman now directly owns 9,994 shares in the company, valued at $4,987,006. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction on Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the sale, the director now directly owns 4,435 shares of the company’s stock, valued at approximately $2,217,500. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Jeffrey M. Leiden sold 3,784 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the completion of the sale, the chairman now directly owns 9,994 shares of the company’s stock, valued at $4,987,006. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX traded down $7.15 on Thursday, hitting $487.46. The company had a trading volume of 156,796 shares, compared to its average volume of 1,168,280. The firm has a 50 day moving average of $476.13 and a two-hundred day moving average of $470.48. The stock has a market capitalization of $125.54 billion, a price-to-earnings ratio of -248.55 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a 52 week low of $341.90 and a 52 week high of $519.88. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period last year, the firm posted $3.67 earnings per share. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on VRTX shares. Guggenheim lifted their target price on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Truist Financial restated a “buy” rating and set a $550.00 target price (up previously from $508.00) on shares of Vertex Pharmaceuticals in a research note on Monday, August 5th. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, July 26th. JPMorgan Chase & Co. reduced their price objective on Vertex Pharmaceuticals from $510.00 to $503.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. Finally, Morgan Stanley increased their target price on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $499.12.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.